Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.
Q2 2008 Financial Highlights

- Product sales up 40% to $706m

- Product sales excluding ADDERALL XR(R) up 64% to $409m

- New product sales(1) $243m, 34% of product sales (2007: 18%)

- Total revenues up 35% to $776m

- US GAAP earnings per ADS: loss $0.44 (2007: loss $9.93)

- Non GAAP earnings per ADS up 70% to $0.95 (2007: $0.56)

- Revenue guidance upgraded - 2008 revenue growth now expected to

be at least 20% (previous guidance: mid to high teens)

(1) New product sales comprise DAYTRANA, ELAPRASE, FOSRENOL, LIALDA /

MEZAVANT and VYVANSE

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver strong growth and broaden its business in specialty biopharmaceuticals. Our product sales for the quarter were up 40% on Q2 2007 with sales of new products now comprising 34% of total product sales. At $409m, product sales excluding ADDERALL XR were up 64% reflecting the success of our strategy to build a pipeline and portfolio for Shire's future growth.

"We are pleased with the performance of ELAPRASE, FOSRENOL, LIALDA, REPLAGAL and VYVANSE and are looking forward to the continued growth of VYVANSE in the US supplemented by the recent launch of the adult indication, the additional dosage strengths and the back-to-school season.

"We have decided to commence a phased discontinuation of DYNEPO. Resources supporting this product will be re-directed to faster growing, profitable core global products.

"The proposed acquisition of Jerini AG in Germany, which we expect to complete in Q3, is an excellent match for our business and we expect to benefit from both its near term revenues and long term growth. The recent EU approval of Je
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  The University of California, San Diego,s Center ... San Diego Extension announced their third annual workshop ... – 14, 2015, at UC San Diego (see ... intense exposure to best practices and the latest ... biologists, process engineers and business executives planning next ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by ... the most dynamic collection of legal medical cannabis stories ever assembled. , ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... 7736892 B2. Under the terms of the agreement, MediVet will acquire the rights ... Cells (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... , , BOTHELL, Wash., Aug. 7 ... reported financial results for the three and six months ended June ... Morra, SCOLR Pharma,s President and CEO, said, "We continue to advance ... release ibuprofen. These potential partners have been committing resources to due ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation ... the distribution rights, along with the trademark, inventory and ... product line. Under the terms of the agreement, the ... existing OsseoFit distribution agreement. Pursuant to the agreement, following ...
... , CORAL GABLES, Fla., Aug. 7 Catalyst Pharmaceutical Partners, Inc. ... and six months ended June 30, 2009. , , ... For the quarter ended June 30, 2009, the Company reported a net loss ... loss of $2,377,440, or $0.19 per basic and diluted share for the same ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... a major food source for much of the world, rice is ... safe from disease has become, in part, the task of a ... Kansas State University. The researchers are looking at two bacterial ... which is caused by a bacterium called Xanthomonas oryzae pathovar ...
... Engineers at Oregon State University have made a major ... run a cooling system a technology that can improve ... will appear in automobiles, homes and industry. This heat-actuated ... the U.S. Army, could ultimately be applied to automobiles, factories ...
... herders are facing the challenges of adapting to climate ... for herds to find food and navigate. To help ... them with satellite-based snow maps. "Snow is of ... whether reindeer are able to access the pastures that ...
Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Breakthrough made in energy efficiency, use of waste heat 2Breakthrough made in energy efficiency, use of waste heat 3Satellite snow maps help reindeer herders adapt to a changing Arctic 2
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: